Michael Joyce,Wei‐Hung Chen,Rajeshwer S. Sankhala,Agnes Hajduczki,Paul V. Thomas,Misook Choe,Elizabeth J. Martinez,William C. Chang,Caroline E. Peterson,Elaine B. Morrison,Clayton Smith,Rita E. Chen,Aslaa Ahmed,Lindsay Wieczorek,Alexander Anderson,James Brett Case,Yifan Li,Therese Oertel,Lorean Rosado,Akshaya Ganesh
The need for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) next-generation vaccines has been highlighted by the rise of variants of concern (VoCs) and the long-term threat of emerging coronaviruses. Here, we design and characterize four categories of engineered nanoparticle immunogens that recapitulate the structural and antigenic properties of the prefusion SARS-CoV-2 spike (S), S1, and receptor-binding domain (RBD). These immunogens induce robust S binding, ACE2 inhibition, and authentic and pseudovirus neutralizing antibodies against SARS-CoV-2. A spike-ferritin nanoparticle (SpFN) vaccine elicits neutralizing titers (ID